Protalix BioTherapeutics, Inc. (DE) Common Stock (NY:PLX)

2.610 +0.020 (+0.77%)

Official Closing Price Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Protalix BioTherapeutics, Inc. (DE) Common Stock

< Previous 1 2 3 4 5 Next >

Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond ↗

March 17, 2025

Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025.

Via Benzinga

Earnings Scheduled For March 17, 2025 ↗

March 17, 2025

Via Benzinga

Earnings Outlook For Protalix BioTherapeutics ↗

November 13, 2024

Via Benzinga

Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm

September 17, 2024

From Kaskela Law LLC

Via Business Wire

Earnings Preview: Protalix BioTherapeutics ↗

March 13, 2024

Via Benzinga

Earnings Scheduled For November 6, 2023 ↗

November 06, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.

Via Benzinga

Earnings Preview For Protalix BioTherapeutics ↗

November 03, 2023

Via Benzinga

Earnings Scheduled For November 14, 2024 ↗

November 14, 2024

Via Benzinga

Life Sciences Virtual Investor Forum Agenda Announced for September 19th

September 16, 2024

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

PLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Beats Revenue for Q2 2024 ↗

August 14, 2024

PLX stock results show that Protalix BioTherapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 17, 2024

Via Benzinga

PLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Misses Revenue for Q1 2024 ↗

May 10, 2024

PLX stock results show that Protalix BioTherapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Preview: Protalix BioTherapeutics's Earnings ↗

August 04, 2023

Via Benzinga

Protalix Clocks 40% Decline In Q1 Revenues Reflecting Lower Sales To Brazil ↗

May 04, 2023

Via Benzinga

Earnings Preview For Protalix BioTherapeutics ↗

February 24, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 10, 2024

Via Benzinga

Earnings Scheduled For March 14, 2024 ↗

March 14, 2024

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

Via Benzinga

Looking Into Protalix BioTherapeutics's Return On Capital Employed ↗

December 23, 2022

Via Benzinga

Protalix BioTherapeutics Well Placed to Advance in 2023 ↗

December 12, 2022

We see a number of reasons to be positive about PLX shares in 2023 and investors should take note.

Via Talk Markets

Pullix Gains Momentum As Gamestop Exits NFT Space ↗

January 14, 2024

Notable NFT news this week is from video game retailer GameStop, which has announced its NFT marketplace will shut down next month. The publicly-traded company is citing “regulatory uncertainty” for...

Via Talk Markets

Protalix BioTherapeutics And 2 Other Penny Stocks Insiders Are Buying ↗

October 23, 2023

The Dow Jones closed lower by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 07, 2023

Via Benzinga

Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics ↗

May 10, 2023

The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

May 10, 2023

It's time for another dive into the biggest pre-market stock movers as we see what shares are on rising and falling on Tuesday!

Via InvestorPlace

Why Lucira Health Shares Are Trading Higher By Over 228%; Here Are 20 Stocks Moving Premarket ↗

February 27, 2023

Gainers Lucira Health, Inc. (NASDAQ: LHDX) rose 228.5% to $0.46 in pre-market trading after the FDA authorized Lucira's over-the-counter at-home test to detect both influenza and COVID-19 viruses.

Via Benzinga

$12.5 Million Bet On Biodesix? Check Out These 4 Penny Stocks Insiders Are Buying ↗

January 06, 2023

The Dow Jones closed lower by more than 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment

November 30, 2022

By David Willey, Benzinga

Via News Direct

Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment

November 30, 2022

Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, have resubmitted a Biologics License...

Via TheNewswire.com

Earnings Scheduled For February 27, 2023 ↗

February 27, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.

Via Benzinga

Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment ↗

November 29, 2022

Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group,

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.